Email Updates
Go to Basic Search
Results
Total Results: 1,886 records
Showing results for "1".
-
srdr.ahrq.gov/projects/1312/studies/182304January 01, 2018 - Key Questions Addressed 1 Is dietary intake of flavan-3ols associated with cardiovascular … Exposure 1 flavanol rich cocoa Comments ( 0 ) | Post/View … 2 Control 1 placebo Comments ( 0 ) | Post/View … Control 1 0 weeks N Analyzed 17 18 … Control 1 0 weeks N Analyzed 17 18
-
srdr.ahrq.gov/projects/1312/studies/182267January 01, 2018 - Safety and Efficacy of Daily Ingestion of Green Tea ( Key Questions Addressed 1 … Exposure 1 Yabukita green tea Comments ( 0 ) | Post/View … 2 Control 1 barley tea- Placebo Comments ( 0 ) | Post/View … Control 1 0 weeks N Analyzed 40 40 … Control 1 0 weeks N Analyzed 38 37
-
srdr.ahrq.gov/projects/1312/studies/182300January 01, 2018 - Key Questions Addressed 1 Is dietary intake of flavan-3ols associated with cardiovascular … Extraction Form: Extraction Form Arms Number Title Description Comments 1 … Exposure 1 High dose- double dose of apple extract Comments ( 0 ) | Post … /View 2 Control 1 placebo Comments ( 0 ) | Post/View … Control 1 0 days N Analyzed 42 42
-
srdr.ahrq.gov/projects/1312/studies/182268January 01, 2018 - Key Questions Addressed 1 Is dietary intake of flavan-3ols associated with cardiovascular … Exposure 1 GTE Comments ( 0 ) | Post/View 2 Control 1 … Control 1 0 weeks N Analyzed 36 37 … Control 1 0 weeks N Analyzed 36 37 … Control 1 0 weeks N Analyzed 36 37
-
srdr.ahrq.gov/projects/1312/studies/182299January 01, 2019 - Key Questions Addressed 1 Is dietary intake of flavan-3ols associated with cardiovascular … Extraction Form: Extraction Form Arms Number Title Description Comments 1 … Exposure 1 cacao procyanidin Comments ( 0 ) | Post/View … 2 Control 1 placebo Comments ( 0 ) | Post/View … Control 1 0 weeks N Analyzed Mean SD
-
srdr.ahrq.gov/projects/1634/studies/193577January 01, 2019 - Key Questions Addressed 1 What are the Objective response rates (ORR), Complete remission … Extraction Form: Phase 1 and 2 trials that looked at the effect of IDH inhibitors in AML patients. … Arms Number Title Description Comments 1 Phase 1/2 study looking at the … Post/View Baseline Characteristics Question Phase 1/ … Adverse Events Arm or Total Title Description Comments Phase 1/2 study
-
srdr.ahrq.gov/projects/1634/studies/193578January 01, 2018 - Key Questions Addressed 1 What are the Objective response rates (ORR), Complete remission … Comments ( 0 ) | Post/View Extraction Form: Phase 1 … Arms Number Title Description Comments 1 Phase 1/2 study evaluating the … Phase 1/2 study evaluating the role of Ivosidenib in RR AML. … Total Phase 1/2 study evaluating the role of Ivosidenib in RR AML.
-
srdr.ahrq.gov/projects/1671/studies/196205January 01, 2020 - alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) … function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 … day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1)
-
srdr.ahrq.gov/projects/1671/studies/196394January 01, 2018 - alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) … function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 … day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1)
-
srdr.ahrq.gov/projects/1671/studies/196130January 01, 2019 - alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) … function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 … day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1)
-
srdr.ahrq.gov/projects/1671/studies/196134January 01, 2019 - alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) … function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 … day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1)
-
srdr.ahrq.gov/projects/1671/studies/196166January 01, 2018 - alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) … function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 … day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1)
-
srdr.ahrq.gov/projects/1671/studies/196160January 01, 2019 - alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) … function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 … day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1)
-
srdr.ahrq.gov/projects/1671/studies/196146January 01, 2019 - alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) … function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 … day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1)
-
srdr.ahrq.gov/projects/1671/studies/196170January 01, 2019 - alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) … function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 … day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1)
-
srdr.ahrq.gov/projects/1671/studies/196098January 01, 2020 - alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) … function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 … day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1)
-
srdr.ahrq.gov/projects/1671/studies/196137January 01, 2018 - alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) … function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 … day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1)
-
srdr.ahrq.gov/projects/1671/studies/196129January 01, 2019 - alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) … function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 … day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1)
-
srdr.ahrq.gov/projects/1671/studies/196132January 01, 2018 - alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) … function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 … day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1)
-
srdr.ahrq.gov/projects/1671/studies/196111January 01, 2019 - alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) … function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 … day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1)
SHARE:
Search the AHRQ Archive
Information and reports more than 5 years old may be found in the AHRQ Archive site.
Search Within A Specific AHRQ Site
You selected to view results for the following site:
